These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 34422667)

  • 41. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NK Cell-Based Immunotherapy for Hematological Malignancies.
    Sivori S; Meazza R; Quintarelli C; Carlomagno S; Della Chiesa M; Falco M; Moretta L; Locatelli F; Pende D
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31623224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.
    Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I
    Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advantages and applications of CAR-expressing natural killer cells.
    Glienke W; Esser R; Priesner C; Suerth JD; Schambach A; Wels WS; Grez M; Kloess S; Arseniev L; Koehl U
    Front Pharmacol; 2015; 6():21. PubMed ID: 25729364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.
    Li YR; Dunn ZS; Zhou Y; Lee D; Yang L
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.
    Zhang L; Liu M; Yang S; Wang J; Feng X; Han Z
    Am J Cancer Res; 2021; 11(4):1770-1791. PubMed ID: 33948388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.
    Mohammad Taheri M; Javan F; Poudineh M; Athari SS
    J Transl Med; 2024 Aug; 22(1):736. PubMed ID: 39103889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting.
    Grote S; Mittelstaet J; Baden C; Chan KC; Seitz C; Schlegel P; Kaiser A; Handgretinger R; Schleicher S
    Oncoimmunology; 2020 Sep; 9(1):1825177. PubMed ID: 33457105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.
    Wang JN; Gu T; Hu Y; Huang H
    Exp Hematol Oncol; 2022 Sep; 11(1):61. PubMed ID: 36153595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
    Romanski A; Uherek C; Bug G; Seifried E; Klingemann H; Wels WS; Ottmann OG; Tonn T
    J Cell Mol Med; 2016 Jul; 20(7):1287-94. PubMed ID: 27008316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Progress of CAR-NK Therapy in Cancer Treatment.
    Pang Z; Wang Z; Li F; Feng C; Mu X
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [